Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials

Diabetes Research and Clinical Practice

Volumn 121, Issue , 2016, Pages 69-85

  Anyanwagu, U ^a   Mamza, J ^a   Donnelly, R ^a   Idris, I ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cardiovascular; Insulin; Meta analysis; Metabolic; Non insulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG THERAPY; GASTROINTESTINAL PAIN; GLUCOSE LOWERING THERAPY; GLYCEMIC CONTROL; HEADACHE; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INFLUENZA; META ANALYSIS; MORTALITY RISK; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SYSTEMATIC REVIEW; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GLYCEMIC INDEX; MALE; METABOLISM; MIDDLE AGED; MORTALITY; RISK; SURVIVAL RATE; TREATMENT OUTCOME;

BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RISK; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84988358440     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.09.002     Document Type: Article

References (62)

1. [1] Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American diabetes association and the European Association for the study of diabetes. Diabetes Care 32 (2009), 193–203.
2. [2] Kahn, S.E., Haffner, S.M., Heise, M.A., Herman, W.H., Holman, R.R., Jones, N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006), 2427–2443.
3. [3] Holman, R.R., Sourij, H., Califf, R.M., Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383 (2014), 2008–2017.
4. [4] Department of Health and Human Services, Food and Drug Administration, centre for Drug Evaluation and Research. Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December 2008. Available at: < http://www.fda.gov/download/Drugs/GuidancecomplianceRegulatoryInformation/Guidance/ucm071627.pdf>.
5. [5] Keen, H., Glynne, A., Pickup, J., et al. Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men. Lancet 2 (1980), 398–401.
6. [6] Malmberg, K., Ryden, L., Wedel, H., et al. ASTTRACK intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26 (2005), 650–661.
7. [7] Cahn, A., Miccoli, R., Dardano, A., Del Prato, S., New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol 3 (2015), 638–652.
8. [8] Bliss, M., The history of insulin. Diabetes Care 16 (1993), 4–7.
9. [9] Pontiroli, A., Miele, L., Morabito, A., Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 14 (2012), 433–446.
10. [10] Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. 18th ed. United States: Massachussetts Medical Society (860 Winter Street, Waltham MA 02451-1413, United States); 2009. p. 1736–47.
11. [11] Van Avendonk, M.J.P., Rutten, G.E.H.M., Insulin therapy in type 2 diabetes: what is the evidence?. Diabetes Obes Metab 11 (2009), 415–432.
12. [12] Rensing, K.L., Reuwer, A.Q., Arsenault, B.J., von der Thusen, J.H., Hoekstra, J.B., Kastelein, J.J., et al. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?. Diabetes Obes Metab 13 (2011), 1073–1087.
13. [13] Currie, C.J., Poole, C.D., Evans, M., Peters, J.R., Morgan, C.L., Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 98 (2013), 668–677.
14. [14] Roumie, C.L., Greevy, R.A., Grijalva, C.G., et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 311 (2014), 2288–2296.
15. [15] Aschner, P., Chan, J., Owens, D.R., Picard, S., Wang, E., Dain, M.-P., et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 379 (2012), 2262–2269.
16. [16] Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M, Exubera Phase IIISG. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. 6th ed. 2006. p. 1282–7.
17. [17] Endnote TR. Thomson Reuteurs Endnote. Available at < www.endnote.com>.
18. [18] Higgins J, Green Se. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
19. [19] The ORIGIN Trial Investigators, Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
20. [20] Mellbin, L.G., Malmberg, K., Norhammar, A., Wedel, H., Ryden, L., Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 54 (2011), 1308–1317.
21. [21] Barnett, A.H., Burger, J., Johns, D., Brodows, R., Kendall, D.M., Roberts, A., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 29 (2007), 2333–2348.
22. [22] Bunck, M.C., Diamant, M., Corner, A., Eliasson, B., Malloy, J.L., Shaginian, R.M., et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32 (2009), 762–768.
23. [23] D'Alessio, D., Haring, H.U., Charbonnel, B., de Pablos-Velasco, P., Candelas, C., Dain, M.P., et al. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. 2nd ed., 2015, Blackwell Publishing Ltd, United Kingdom, 170–178.
24. [24] Davies M, Heller S, Sreenan S, Sapin H, Adetunji O, Tahbaz A, et al. Once-weekly exenatide vs once- or twicedaily insulin detemir: randomised, openlabel clinical trial of efficacy and safety in patients with type 2 diabetes inadequately controlled with metformin alone or with sulphonylureas. 2013;30:57–8.
25. [25] Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study. 12th ed. United Kingdom: Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom); 2009. p. 1153–62.
26. [26] Diamant, M., Van Gaal, L., Stranks, S., Guerci, B., MacConell, L., Haber, H., et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 35 (2012), 683–689.
27. [27] Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. 9733 ed. United Kingdom: Elsevier Limited (32 Jamestown Road, London NW1 7BY, United Kingdom); 2010. p. 2234–43.
28. [28] Diamant M, Nauck MA, Shaginian R, Wolffenbuttel BH, Grp BS, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. 10th ed. 2014. p. 2763–73.
29. [29] Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. 2009;8.
30. [30] Heine, R.J., Van Gaal, L.F., Johns, D., Mihm, M.J., Widel, M.H., Brodows, R.G., Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143 (2005), 559–569.
31. [31] Matyjaszek-Matuszek B, Lenart-Lipinska M, Rogalska D, Nowakowski A. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland – Subgroup data from a randomised multinational trial GWAA. 2013;64:375–82.
32. [32] Philis-Tsimikas A, Del Prato S, Satman I, Bhargava A, Dharmalingam M, Skjoth TV, et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. 2013;15:760–6.
33. [33] Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. 3rd ed. United States: American Diabetes Association Inc. (1701 North Beauregard St., Alexandria VA 22311, United States); 2006. p. 554–9.
34. [34] DeWit, H., Vervoort, G.M., Jansen, H.J., De Grauw, W.J.C., De Galan, B.E., Tack, C.J., Liraglutide reverses pronounced insulin-associated weight gain, improves glycemic control, and decreases insulin dose in patients with type 2. Diabetes 63 (2014), A50–A249.
35. [35] Moher, D., Pham, B., Jones, A., Cook, D.J., Jadad, A.R., Moher, M., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 352 (1998), 609–613.
36. [36] United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical research ed). 1995;310:83–8.
37. [37] United Kingdom Prospective Diabetes Study (UKPDS) 38: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ (Clinical research ed). 1998;317:703–13.
38. [38] Ray, K.K., Seshasai, S.R.K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (2009), 1765–1772.
39. [39] Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical Research Ed) 321 (2000), 405–412.
40. [40] Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F.L., Powe, N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004), 421–431.
41. [41] Currie, C.J., Peters, J.R., Tynan, A., Evans, M., Heine, R.J., Bracco, O.L., et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375 (2010), 481–489.
42. [42] Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. 1st ed. United Kingdom: Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom); 2013. p. 42–54.
43. [43] Shaefer CF, Reid TS, Dailey G, Mabrey ME, Zhou R, et al. Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes. 6th ed. 2014. p. 93–105.
44. [44] Venables, M.C., Jeukendrup, A.E., Physical inactivity and obesity: links with insulin resistance and type 2 diabetes mellitus. Diabetes/Metabolism Res Rev 25:Suppl 1 (2009), S18–S23.
45. [45] Russell-Jones, D., Khan, R., Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes Obes Metab 9 (2007), 799–812.
46. [46] Dornhorst, A., Luddeke, H.J., Sreenan, S., Koenen, C., Hansen, J.B., Tsur, A., et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort. 3rd ed., 2007, Blackwell Publishing Ltd, United Kingdom, 523–528.
47. [47] Wilson, P., McGee, D., Kannel, W., Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: the Framingham Study. Am J Epidemiol 114 (1981), 697–704.
48. [48] Kannel, W.B., D'Agostino, R.B., Cobb, J.L., Effect of weight on cardiovascular disease. Am J Clin Nutrition 63 (1996), 22S–419S.
49. [49] The UK Prospective Diabetes Study Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
50. [50] Guillausseau PJ, Virally M, Kevorkian JP, Meas T, Laloi-Michelin M, Ambonville C, et al. Intensive blood suger control in type 2 diabetes: Results of recent interventional trials (ADVANCE, VA Diabetes Trial and ACCORD). 1st ed. France: John Libbey Eurotext (127, avenue de la Republique, Montrouge 92120, France); 2009. p. 15–22.
51. [51] The ADVANCE Collaborative Group, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
52. [52] The Action to Control Cardiovascular Risk in Diabetes Study Group, Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
53. [53] Koska J, Saremi A, Bahn G, Yamashita S, Reaven PD. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). 8th ed. United States 2013. p. 2408–14.
54. [54] Yakubovich, N., Gerstein, H.C., Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 123 (2011), 342–348.
55. [55] Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study; 2010.
56. [56] Svensson, A.-M., McGuire, D.K., Abrahamsson, P., Dellborg, M., Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 26 (2005), 1255–1261.
57. [57] Frier, B.M., Schernthaner, G., Heller, S.R., Hypoglycemia and cardiovascular risks. Diabetes Care 34 (2011), S132–S137.
58. [58] McCrimmon, R.J., Frier, B.M., Hypoglycaemia, the most feared complication of insulin therapy. Diabete Metabolisme 20 (1994), 503–512.
59. [59] Hemmingsen, B., et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev, 11, 2013, CD008143, 10.1002/14651858.CD008143.pub3.
60. [60] Colayco, D.C., Niu, F., McCombs, J.S., Cheetham, T.C., A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 34 (2011), 77–83.
61. [61] Hu, F.B., Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34 (2011), 1249–1257.
62. [62] National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. 2009. Available at: < https://www.nice.org.uk/guidance/cg87/chapter/1-Guidance>.